UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~SECURITIES~~For the ~~EXCHANGE~~month ~~ACT~~of January, ~~OF 1934~~2008

For the month of December, 2007

Commission File Number 0-30860

Axcan Pharma Inc.

(~~Translation~~Exact Name of ~~registrant’s name into English~~Registrant)

597, boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F o Form 40-F x

~~Form~~Indicate by ~~20-F~~check o mark if the registrant is submitting the Form 6-K 40in paper as permitted by Regulation S-FT xRule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(17): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate the file number assigned to the registrant in connection with Rule 12g3-2(b):

82-

Exhibit No.		Description
99.1		Material Change Report of Axcan Pharma Inc., dated December 4, 2007

This Form 6-K consists of a January 21, 2008 press release entitled “Axcan Pharma Announces Topline Financial Information for Q1 2008”.

–2–

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AXCAN PHARMA INC.
Date: December 4, 2007	By:	/s/ Richard Tarte
Date: January 23, 2008	By:	/s/ Richard Tarte
	Name:	Richard Tarte
	Title:	Vice President, Corporate Development
		and General Counsel

~~–3–~~2

Filing Compare · AXCAN PHARMA INC